Cancer is a disease characterized by abnormal cell growth that has the ability to invade and spread to other organs of the body. Epidermal Growth Factor Receptor (EGFR) is a subgroup of receptor tyrosine kinase that activate various biological responses including mitogenesis, migration, differentiation, and apoptosis. EGFR activity affects the growth of cancer cells. Bioactive peptides can be an alternative as an inhibitor of EGFR activity. Tilapia is a source of bioactive peptides that have a high protein content and complete amino acids. This study aims to obtain a new bioactive peptide candidate from tilapia myosin (Oreochromis niloticus) as an inhibitor of EGFR activity with parameters of ΔG and residue interactions on tyrosine kinase (PDB ID: 6LUD) using virtual screening, SwissADME, and molecular docking. The molecular docking results showed that ER and AGK peptides had the lowest ΔG values ??with values ??of -10.45 kcal/mol and -10.59 kcal/mol. The interaction of amino acid residues on ER peptides are ARG-836, ARG-858, ASP-837, ASP-855, LYS-875, GLU-758, PHE-723, PHE-856, GLY-857, LYS-860, HSE- 835, ASN-842, ARG-841, PRO-877, VAL-876, ALA-871, LYS-875, GLY-874, GLY-873, and GLU-872. The interactions of amino acid residues on AGK peptides are ARG-836, ASP-837, ASP-855, GLU-758, LYS-875, LYS-754, LYS-757, LYS-860, GLU-872, PHE-723, GLY- 857, ARG-858, ARG-836, ASN-842, ARG-841, PRO-877, VAL-876, TYR-869, GLY-874, ALA-871, and GLY-873. ER and AGK peptides have potential as anticancer drugs with a bioavailability score is 0.55, does not have allergen and toxin properties, good water solubility and pass the Lipinski test.